Welcome to Iris Biotech
For better service please confirm your country and language we detected.
Währung
EUR
Schneller Kontakt
Bitte senden Sie mir mehr Informationen über
cyclo-[RGDfK(TPP)]
Chemischer Name: cyclo[arginyl-glycyl-aspartyl-D-phenylalanyl-epsilon-(triphenylphosphonium)-lysyl]
- Art-Nr.:LS-3920
- CAS Nr.:1926210-57-2
- Formel:C50H63N9O8P+Br-
- Molare Masse:949,06*79,90 g/mol
Startet von 250,00 €
description
A synthetic cyclic RGD peptide that induces the formation of multicellular tumour spheroids (MTS), which serve as 3D in vitro models that mimic the in vivo tumour environment. Cyclo-RGDfK(TPP) induces self-assembly in certain tumour cell lines via interaction with alpha-5 beta-1 integrins. Moreover, the peptide also initiates the formation of 3D spheroids in several cell lines of both normal and stem cells. Those spheroids are valuable tools for the design of 3D in vitro models, as well as for tissue regeneration experiments.
references
3D in vitro co-culture models based on normal cells and tumor spheroids formed by cyclic RGD-peptide induced cell self-assembly; R. Akasov, A. Gileva, D. Zaytseva-Zotova, S. Burov, I. Chevalot, E. Guedon and E. Markvicheva; Biotechnology Letters 2017; 39: 45-53. doi:10.1007/s10529-016-2218-9
Sialylation facilitates self-assembly of 3D multicellular prostaspheres by using cyclo-RGDfK(TPP) peptide; S. Haq, V. Samuel, F. Haxho, R. Akasov, M. Leko, S. V. Burov, E. Markvicheva and M. R. Szewczuk; OncoTargets and therapy 2017; 10: 2427-2447. doi:10.2147/ott.s133563
Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD-peptide induced self-assembly; R. Akasov, S. Haq, F. Haxho, V. Samuel, S. V. Burov, E. Markvicheva, R. J. Neufeld and M. R. Szewczuk; Oncotarget 2016; 7: 66119-66134. doi:10.18632/oncotarget.11868
Formation of multicellular tumor spheroids induced by cyclic RGD-peptides and use for anticancer drug testing in vitro; R. Akasov, D. Zaytseva-Zotova, S. Burov, M. Leko, M. Dontenwill, M. Chiper, T. Vandamme and E. Markvicheva; International Journal of Pharmaceutics 2016; 506: 148-157. doi:https://doi.org/10.1016/j.ijpharm.2016.04.005
Bulk oder Großmengen-Bestellung?
Sie benötigen größere Mengen für Ihre Entwicklung oder Produktion?
Benötigen Sie weitere Informationen über dieses Produkt?
kontaktieren Sie uns
Verwandte Produkte
![Structure image for E[c(RGDfK)]c(RGDfK)](https://www.iris-biotech.de/media/catalog/product/L/S/LS-3980.svg?width=240&height=140&store=de&image-type=small_image)
![Structure image for ICG-E[c(RGDfK)]2](https://www.iris-biotech.de/media/catalog/product/L/S/LS-3950.svg?width=240&height=140&store=de&image-type=small_image)
![Structure image for cyclo-[RGDfK(TPP)]](https://www.iris-biotech.de/media/catalog/product/L/S/LS-3920.svg?width=240&height=140&store=de&image-type=small_image)
Produkte, die Sie auch interessieren könnten!
![Structure image for ICG-E[c(RGDfK)]2](https://www.iris-biotech.de/media/catalog/product/L/S/LS-3950.svg?width=216&height=140&store=de&image-type=small_image)
![Structure image for E[c(RGDfK)]c(RGDfK)](https://www.iris-biotech.de/media/catalog/product/L/S/LS-3980.svg?width=216&height=140&store=de&image-type=small_image)
